Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.38 |
| ▸ | GPR183 | P32249 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL299187 | 0.87 | PTGS2 (0.44) | RAB9ANPC1PTGS2CASP3SENP8 | |
| SCHEMBL290316 | 0.84 | PTGS2 (0.46) | RAB9ANPC1PTGS2PRKCIERN1 | |
| SCHEMBL299578 | 0.83 | SRD5A2 (0.46) | RAB9ANPC1PTGS2CASP3SENP7 | |
| SCHEMBL290225 | 0.77 | PTGS2 (0.52) | RAB9ANPC1PTGS2CASP3SENP8 | |
| SCHEMBL290073 | 0.76 | PTGS2 (0.52) | RAB9ANPC1PTGS2CASP3SENP8 | |
| SCHEMBL290295 | 0.76 | PTGS2 (0.51) | RAB9ANPC1PTGS2CASP3SENP8 | |
| SCHEMBL289809 | 0.76 | PTGS2 (0.68) | RAB9ANPC1PTGS2CASP3SENP8 | |
| SCHEMBL290525 | 0.76 | PDF (0.53) | RAB9ANPC1PTGS2CASP3SENP8 | |
| SCHEMBL290323 | 0.76 | PTGS2 (0.56) | RAB9ANPC1PTGS2CASP3SENP8 | |
| SCHEMBL11022359 | 0.73 | PRKCI (0.66) | RAB9ANPC1PRKCIERN1TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2959898-A1 | 4,5-DIOXO-NAPHTHO[1,2-b]FURANS AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS | Sloan-Kettering Institute for Cancer Research (US) | 2015-12-30 | — | — | EP | disclosed |
| EP-2427057-B1 | BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS | SLOAN KETTERING INST CANCER (US) | 2015-08-12 | — | — | EP | disclosed |
| US-8614237-B2 | Benzofuran-4,5-diones as selective peptide deformylase inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2013-12-24 | — | — | US | disclosed |
| US-20120071523-A1 | BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2012-03-22 | — | — | US | disclosed |
| EP-2427057-A1 | BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS | Sloan-Kettering Institute for Cancer Research (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129049-A1 | BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071523-A1 | BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS | PDF, EIF5B, EIF4E | RAB9A 3434/4885NPC1 1866/4885PTGS2 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.